Literature DB >> 10640968

Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.

B Sadeghi1, C Arvieux, O Glehen, A C Beaujard, M Rivoire, J Baulieux, E Fontaumard, A Brachet, J L Caillot, J L Faure, J Porcheron, J L Peix, Y François, J Vignal, F N Gilly.   

Abstract

BACKGROUND: Peritoneal carcinomatosis (PC) is a common evolution of digestive cancer, associated with a poor prognosis. Yet it is poorly documented in the literature.
METHODS: Three hundred seventy patients with PC from non-gynecologic malignancies were followed prospectively: the PC was of gastric origin in 125 cases, of colorectal origin in 118 cases, of pancreatic origin in 58 cases, of unknown origin in 43 cases, and of miscellaneous origins in 26 cases. A previously reported PC staging system was used to classify these 370 patients.
RESULTS: Mean and median overall survival periods were 6.0 and 3.1 months, respectively. Survival rates were mainly affected by the initial PC stage (9.8 months for Stage I with malignant peritoneal granulations less than 5 mm in greatest dimension, versus 3.7 months for Stage IV with large, malignant peritoneal masses more than 2 cm in greatest dimension). The presence of ascites was associated with poor survival of patients with gastric or pancreatic carcinoma. Differentiation of the primary tumor did not influence the prognoses of patients with PC.
CONCLUSIONS: A better knowledge of the natural history of PC is needed, in view of the many Phase I, II, and III trials currently being conducted to evaluate aggressive multimodal therapeutic approaches to treating patients with PC from non-gynecologic malignancies. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10640968     DOI: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  317 in total

1.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

Authors:  Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies.

Authors:  Pedro Bretcha-Boix; Jose Farré-Alegre; Manuel Sureda; Carlos Dussan; Juan José Pérez Ruixo; Antonio Brugarolas Masllorens
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

3.  Clinical outcomes according to primary treatment in gastric cancer patients with peritoneal seeding.

Authors:  Jung Min Bae; Kyoung Joon Yeo; Se Won Kim; Sang Woon Kim; Sun Kyo Song
Journal:  J Gastric Cancer       Date:  2011-09-29       Impact factor: 3.720

4.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

5.  Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Martin Graversen; Sönke Detlefsen; Jon Kroll Bjerregaard; Per Pfeiffer; Michael Bau Mortensen
Journal:  Clin Exp Metastasis       Date:  2017-05-17       Impact factor: 5.150

6.  [Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy].

Authors:  G Glockzin; N Ghali; S A Lang; A Agha; H J Schlitt; P Piso
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

Review 7.  Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.

Authors:  Simon Binder; Andrew L Lewis; J-Matthias Löhr; Michael Keese
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis.

Authors:  Hiroaki Aoki; Masayo Aoki; Eriko Katsuta; Rajesh Ramanathan; Michael O Idowu; Sarah Spiegel; Kazuaki Takabe
Journal:  J Surg Res       Date:  2016-07-09       Impact factor: 2.192

9.  Enhanced serum methylated p16 DNAs is associated with the progression of gastric cancer.

Authors:  Yi-Chen Wu; Ping Lv; Jing Han; Jiang-Liu Yu; Xin Zhu; Lian-Lian Hong; Wang-Yu Zhu; Qi-Ming Yu; Xin-Bao Wang; Pei Li; Zhi-Qiang Ling
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 10.  Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies.

Authors:  Yan Li; Yun-Feng Zhou; Han Liang; Hua-Qing Wang; Ji-Hui Hao; Zheng-Gang Zhu; De-Seng Wan; Lun-Xiu Qin; Shu-Zhong Cui; Jia-Fu Ji; Hui-Mian Xu; Shao-Zhong Wei; Hong-Bin Xu; Tao Suo; Shu-Jun Yang; Cong-Hua Xie; Xiao-Jun Yang; Guo-Liang Yang
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.